

OK on Disk 64

MOLECULAR BIOLOGY IN CLASSIFICATION AND ASSESSMENT OF THERAPY IN ADULT AGGRESSIVE NON-HODGKIN'S LYMPHOMA

Thesis


Submitted in partial fulfillment of M.D. degree in Radiotherapy and Nuclear Medicine

BY

616-07575
P. R.

LOBNA RASHED EZZ-ELARAB

M.B., B.Ch., M.Sc.



SUPERVISED BY

60757

Prof. SALWA MASSOUD IBRAHIM

Professor of Radiation Oncology & Nuclear Medicine,

Faculty of Medicine, Ain Shams University

Prof. ADEL ABD EL-KADER

*Professor of General Surgery,
Faculty of Medicine,
Ain Shams University*

Prof. ALI KHALIFA ALI

*Professor of Biochemistry & Tumor Biology,
Faculty of Medicine,
Ain Shams University*

Prof. SOHEIR H. MAHMOUD

*Professor of Radiation Oncology
& Nuclear Medicine,
Faculty of Medicine, Ain Shams University*

DR. AZZA EL-SAID HASHEM

*Lecturer of Clinical Pathology
Faculty of Medicine,
Ain Shams University*

Radiation Oncology & Nuclear Medicine Department

Faculty of Medicine

Ain Shams University

1999

[Handwritten signatures and notes]

1. Introduction

2. Methodology

3. Results

4. Discussion

5. Conclusion

6. References

7. Appendix

8. Glossary

9. Index

10. Bibliography

11. Acknowledgements

12. Author's Note

13. Contact Information

14. Declaration of Interest

15. Funding Statement

16. Data Availability Statement

17. Ethics Statement

18. Consent to Publish



Acknowledgment

First words and foremost thanks to Allah, the most beneficent and merciful.

No words could express my sincere appreciations and deepest gratitude to *Prof. Dr. Salwa Massoud Ibrahim*; Professor of Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University.

Fortunately, this study has been supervised by her who offered me great help and support.

I'm greatly thankful for her suggestion, valuable observations and meticulous revision of every possible details.

She guided me with great patience. The words will never be enough to express my thanks to her continual support and unlimited efforts throughout the whole work.

* * * * *

My sincere appreciation goes to:

*** *Prof. Dr. Ali Khalifa Ali*, Professor of Biochemistry; Head of Oncology Diagnostic Unit, Faculty of Medicine, Ain-Shams University; for his sincere and immense help.**

I'm greatly indebted for his valuable advice, continuous encouragement and indispensable guidance without his support this work would not come into existence.

*** * * * ***

*** *Prof. Dr. Soheir Helmy Mahmoud*, Professor of Radiation Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain-Shams University; for her great and continuous support and advice.**

*** * * * ***

*** *Prof. Dr. Adel Abdel-Kader*, Professor of Surgery, Faculty of Medicine, Ain-Shams University, for his help.**

*** * * * ***

*** *Dr. Azza El-Sayed Hashem*, Lecturer of clinical pathology Faculty of Medicine, Ain-Shams University, for her unlimited efforts throughout the whole work.**

*** * * * ***

Contents

	Page
List of abbreviations	i
List of Tables	iv
List of Figures	vii
Introduction	1
Review of literature	6
Epidemiology	6
Etiology	10
Pathological classification of lymphomas	18
Staging of NHL	29
Prognostic factors for aggressive lymphomas	39
Molecular biology of NHL	54
Immunophenotyping of lymphoid cells	64
Multiple drug resistance	72
Primary extranodal lymphomas	91
Treatment of aggressive NHL	106
High dose therapy with bone marrow transplantation in management of aggressive NHL	118
Subject and Methods	132
Results	163
Discussion	217
Conclusion	231
Summary	233
References	238
Arabic Summary	

List of abbreviations

AIDS	Acquired Immune Deficiency Syndrome
AML	Acute Myelogenous Leukemia
ATP	Adenosine Triphosphate Phosphate
BCBL	Body Cavity Based Lymphoma
BCNU	Bis-Chloroethyl Nitroso Urea
BMT	Bone Marrow Transplantation
BL	Burkitt's Lymphoma
B-SA	Biotin-Streptavidin
CALLA	Common Acute Lymphocytic Leukemia Antigen
CD	Cluster of Disignation
CML	Chronic Myeloid Leukemia
CLL	Chronic Lymphoid Leukemia
CR	Complete Remission
CSF	Collagen Stimulating Factor
CT	Computerized Tomography
CY	Cyclophosphamide
DFS	Disease Free Survival
DLCL	Diffuse Large Cell Lymphoma
DML	Diffuse Mixed Lymphoma
EALT	Entropathy Associated T-cell Lymphoma
EBV	Epstein-Barr Virus
ECOG	Eastern Clinical Oncology Group
EMA	Epithelial Membrane Antigen

FCC	Follicular Center Cell
FFR	Freedom From Relapse
GSH	Glutathione
GVHD	Graft Versus Host Disease
HD	Hodgkin's Disease
HHV	Human Herpes Virus
HIV	Human Immunodeficiency Virus
HLA	Human Leukocyte Antigen
HTLV	Human T-cell Leukemia/Lymphoma Virus
IFRT	Involved Field Irradiation
ILSG	International Lymphoma Study Group
IPI	International Prognostic Index
IPSID	Immunoproliferative Small Intestinal Disease
IV	Intravenous
LDH	Lactic Dehydrogenase
LGL	Large Granular Lymphocytic Leukemia
LHR	Lymphocyte Homing Receptor
MALT	Mucosa-Associated Lymphoid Tissue
MDR	Multiple Drug Resistance
MDS	Myelodysplastic Syndrome
ML	Malignant Lymphoma
MRI	Magnetic Resonance Imaging
MRP	Multidrug Resistance-associated Proteins
NCAM	Neural Cell Adhesion Molecule
NCI	National Cancer Institute
NHL	Non-Hodgkin's Lymphoma

NL	Nasal T-cell Lymphoma
NML	Nodular Mixed Lymphoma
OS	Overall Survival
PBS	Phosphate Bufferd Saline
PBSC	Peripheral Blood Stem Cell Transplantation
PCR	Polymerase Chain Reaction
PD	Progressive Disease
PDL	Poorly Differentiated Lymphoma
PEL	Primary Extranodal Lymphoma
Pgp	P- glycoprotein
PLL	Polydifferentiated lymphocytic lymphoma
PMH	Princess Margaret Hospital
PR	Partial Remission
PTCL	Peripheral T-cell Lymphoma
REAL	Revised European American Lymphoma
SD	Stable Disease
SEER	Survillance,Epidemiology and End Results
SLI-2R	Soluble Interleukin-2 Receptor
SPF	S-Phase Fraction
SWOG	Southwest Oncology Group
TBI	Total Body Irradiation
T-TIL	T-cell Tumor Infiltrating Lymphocyte
UHBI	Upper Half Body Irradiation
VNTR	Variable Number of Tandem Repeats

List of Tables

Table	Title	Page
Table (1)	Known risk factors for NHL	10
Table (2)	Terminology among four classifications schemes of NHL	20
Table (3)	National Cancer Institute (USA) Modification of working formulation for classification of NHL	22
Table (4)	The revised European-American Lymphoma (REAL) classification	23
Table (5)	Comparison of working formulation with REAL classification	25
Table (6)	Staging system of NHL Lymphoma in adult	3
Table (7)	Modification of Ann-Arbor staging system	31
Table (8)	Outcome according to risk group defined by the international NHL prognostic index	4
Table (9)	Equivalence of PS as defined originally by ECOG & Karnovsky index	4
Table (10)	Immunological classification of B-cell lymphomas	6
Table (11)	Immunological classification of T-cell lymphomas	7
Table (12)	Methods of detecting MDR	7
Table (13)	Expression of MDR1 in untreated solid tumors	8
Table (14)	Drugs currently used in clinical trial to reverse MDR	8
Table (15)	Pathological classification of GIL	9
Table (16)	PEL in relation to immunophenotyping	10

Table	Title	Page
Table (36)	Correlation of DNA status with classic prognostic factors	184
Table (37)	Correlation of immunophenotyping with classic prognostic factors	185
Table (38)	Correlation of MDR Pgp expression with other biological markers	186
Table (39)	Correlation of SPF with other biological markers	187
Table (40)	Response rate of 60 adult aggressive NHL patients	192
Table (41)	Clinical laboratory criteria of CR versus those who failed to attain CR	194
Table (42)	Biological markers of CR versus those who failed to attain CR	195
Table (43)	Type of treatment in relation to DFS & OS	198
Table (44)	Predictive value of B2-M on DFS	198
Table (45)	Predictive value of B2-M on OS	198
Table (46)	Predictive value of IPI on DFS & OS	201
Table (47)	Predictive value of response on OS	203
Table (48)	Predictive value of biological markers on OS	206
Table (49)	Predictive value of biological markers on DFS	210
Table (50)	Pattern of treatment failure	211
Table (51)	Different acute toxicity data	214
Table (52)	Causes of death	216

Table	Title	Page
Table (17)	First generation chemotherapy programs for NHL	108
Table (18)	M-BACOD & m-BACOD regimens	112
Table (19)	Third generation chemotherapy programs for NHL	114
Table (20)	Comparison between MACOP-B regimen & ABMT in treatment of newly diagnosed aggressive NHL	120
Table (21)	Comparison between standard consolidation therapy and ABMT in aggressive NHL	120
Table (22)	Monoclonal antibodies used in this analysis	144
Table (23)	CHOP regimen	151
Table (24)	m-BACOP regimen	152
Table (25)	Response of patients to therapy according to UICC criteria	156
Table (26)	Acute normal tissue toxicity according to WHO criteria	157
Table (27)	RTOG acute radiation morbidity scoring criteria	158
Table (28)	RTOG/EORTC late radiation morbidity scoring scheme	160
Table (29)	Pretreatment clinical characteristics of 60 patients with aggressive NHL	164
Table (30)	Site distribution of nodal affection	166
Table (31)	Site distribution of extranodal affection	166
Table (32)	Laboratory & pathological work up results	168
Table (33)	Pretreatment biological characteristics	173
Table (34)	Correlation of MDR Pgp with classic prognostic factors	181
Table (35)	Correlation of SPF with classic prognostic factors	183

List of Figures

Figure	Title	Page
Figure(1)	Different types of lymphoma according to the site & cell of origin	19
Figure(2)	Bone marrow involvement in NHL	34
Figure(3)	Gallium-67 scan shows intense uptake in the submandibular and submental nodes	38
Figure(4)	Monoclonal antibodies to human B cell surface antigen	66
Figure(5)	Monoclonal antibodies to human T cell surface antigen	69
Figure(6)	Cytotoxic signaling pathway involving DNA damage either direct or indirect	75
Figure(7)	Distribution of primary extranodal lymphoma presentation in PMH	93
Figure(8)	Lymphoma of the stomach	95
Figure(9)	Renal involvement in NHL	102
Figure(10)	Pretreatment cardiac radionuclide scintigraphy	133
Figure(11)	Cytospin used for cell suspension	145
Figure(12)	Treatment design for group A	153
Figure(13)	Treatment design for group B	154
Figure(14)	Site distribution of nodal affection in group A & group	167
Figure(15)	Site distribution of extranodal affection in group A & group B	167
Figure(16)	Negative reaction for Pgp in lymphoma cells	171

Figure	Title	Page
Figure(17)	Positive reaction for Pgp in 50% of lymphoma cells	171
Figure(18)	DNA diploid pattern histogram shows low proliferating lymphoid pattern	174
Figure(19)	DNA diploid pattern histogram shows high proliferating lymphoid pattern	175
Figure(20)	DNA histogram shows diploid pattern	176
Figure(21)	DNA histogram shows aneuploid pattern	177
Figure(22)	Immunophenotyping profile of a B-NHL sample	178
Figure(23)	Immunophenotyping profile of a T-NHL sample	179
Figure(24)	Female patient aged 55 years with stage II _{EB} thyroidNH	188
Figure(25)	Female patient aged 65 years with gaped scar	189
Figure(26)	CT of the neck	190
Figure(27)	CT of the left maxillary antrum	191
Figure(28)	Overall survival curve for the group of the studied patients	199
Figure(29)	Overall survival curve in relation to B2-microglobulin	200
Figure(30)	Overall survival curve in relation to IPI	202
Figure(31)	Overall survival curve in relation to response to therapy	202
Figure(32)	Overall survival curve in relation to MDR	207
Figure(33)	Overall survival curve in relation to SPF	208
Figure(34)	Overall survival curve in relation to immunophenotyping	209
Figure(35)	Patterns of treatment failure	212